Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management

Neurology and Therapy
Kristen M Ward, Leslie Citrome

Abstract

Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing movement disorders associated with exposure to dopamine receptor blocking agents such as antipsychotics, but they differ in their pathophysiology and clinical management. Treatment for one may worsen the other, and there are important diagnostic clues that assist in making an accurate assessment and instituting a rational treatment plan. A literature review was executed to identify articles relating to the presentation, pathophysiology, epidemiology, and management of DIP and TD. DIP and TD prevalence estimates range from approximately 20 to 35% among antipsychotic users, but may be higher in select populations. DIP often presents as bradykinesia and rigidity, as well as rhythmic tremor, and the majority of cases appear within hours to weeks of initiation of therapy with an antipsychotic, or if dosage of the antipsychotic is increased. TD onset is delayed, typically appearing after at least 3 months or longer of treatment, and patients will commonly present with involuntary, abnormal facial movements such as lip smacking, puckering, chewing, or tongue protrusion. DIP often resolves with discontinuation of the causative agent, but TD may be permanent. B...Continue Reading

References

May 1, 1976·Archives of General Psychiatry·A DiMascioJ E Marder
Aug 1, 1976·The American Journal of Psychiatry·W E Fann, C R Lake
Sep 1, 1987·The American Journal of Psychiatry·P J WeidenA Frances
Jun 1, 1988·Journal of Neurology, Neurosurgery, and Psychiatry·R J Hardie, A J Lees
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Oct 1, 1994·Journal of Geriatric Psychiatry and Neurology·R A SweetJ M Perel
Jan 1, 1993·The Journal of Neuropsychiatry and Clinical Neurosciences·R A SweetG S Zubenko
Jan 1, 1997·Schizophrenia Bulletin·M F EganR J Wyatt
Apr 30, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D C MamoM S Keshavan
Sep 3, 1999·BMJ : British Medical Journal·P N van HartenR S Kahn
Apr 1, 1997·Journal of Clinical Psychopharmacology·S AngusN M Schneider
Jan 5, 2002·Journal of Neural Transmission·S Hassin-BaerN Giladi
Nov 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Jennifer HallidayRobin McCreadie
May 29, 2003·Chemistry & Biology·Nicole Ballew
Oct 8, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Werner Poewe, Christoph Scherfler
Dec 21, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Howard C MargoleseLawrence Annable
Mar 15, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel Tarsy, Ross J Baldessarini
Nov 23, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Dominic JamoraEng-King Tan
Jan 24, 2007·Journal of Psychiatric Practice·Peter J Weiden
Dec 11, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Christine D Esper, Stewart A Factor
Feb 5, 2009·The Journal of Clinical Psychiatry·Theodore D SatterthwaiteStanley N Caroff
Apr 15, 2009·Current Treatment Options in Neurology·Frandy Susatia, Hubert H Fernandez
Jul 3, 2009·The American Journal of Psychiatry·Sophia VinogradovBruce G Pollock
Oct 29, 2009·European Journal of Nuclear Medicine and Molecular Imaging·Francisco J Diaz-CorralesPablo Mir
Dec 3, 2010·Clinical Neuropharmacology·Sofia PappaSpiridon Konitsiotis
Dec 22, 2010·Neurologic Clinics·Stanley N CaroffE Cabrina Campbell
Jan 19, 2012·Drugs & Aging·José Luis López-SendónJusto García de Yébenes
Apr 24, 2012·Journal of Clinical Neurology·Hae-Won Shin, Sun Ju Chung
Sep 28, 2013·Neuropsychiatric Disease and Treatment·Stacey K Jankelowitz
Jul 30, 2014·Nature Neuroscience·Paolo CalabresiMassimiliano Di Filippo
Oct 26, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Rodolfo SavicaWalter A Rocca
Feb 2, 2017·The Journal of Clinical Psychiatry·Maren CarbonChristoph U Correll
Mar 23, 2017·The American Journal of Psychiatry·Robert A HauserChristopher F O'Brien
Apr 28, 2017·Neurology·Hubert H FernandezKaren E Anderson
Nov 16, 2017·The Journal of Clinical Psychiatry·Stewart A FactorChristopher F O'Brien
Dec 17, 2017·Journal of the Neurological Sciences·Leslie Citrome
Feb 15, 2018·Journal of the Neurological Sciences·Marco SolmiChristoph U Correll

❮ Previous
Next ❯

Citations

Jun 23, 2019·Journal of Neuroscience Research·Chiara CiriachiMattias Rickhag
Jan 29, 2020·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Nicole PizzorniAntonio Schindler
Aug 20, 2019·Current Neurology and Neuroscience Reports·Divya AryaHubert H Fernandez
Oct 31, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Stanley N Caroff
Nov 11, 2019·The Nursing Clinics of North America·Sattaria DilksJessica Johnson
Dec 10, 2020·Clinical Pharmacology : Advances and Applications·Assefa KumsaLiyew Agenagnew
May 1, 2020·Psychiatry Research·Brent M Kious, Amanda V Bakian
Jan 27, 2020·BMJ Neurology Open·Alice PowellMichael William Hayes
Apr 24, 2021·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Stanley N CaroffE Cabrina Campbell
May 7, 2021·Perspectives in Psychiatric Care·Brayden Kameg, Claire Champion
Nov 14, 2020·Expert Review of Neurotherapeutics·Alice PowellSimon J G Lewis
Jul 29, 2021·Clinical Parkinsonism & Related Disorders·Rani Priyanka VasireddyZain Guduru
Aug 10, 2021·Issues in Mental Health Nursing·Barbara WarrenJessica Johnson

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Innovations in Clinical Neuroscience
Katie T B Touma, Jonathan R Scarff
© 2022 Meta ULC. All rights reserved